Interventional study on the effects of hesperidin on hepatic steatosis and inflammation in elderly patients with non-alcoholic fatty liver disease
Objective:To investigate the effect of hesperidin intervention on hepatic steatosis,biochemical and inflammatory parameters in elderly patients with non-alcoholic fatty liver disease(NAFLD).Methods:A total of 120 elderly patients with NAFLD who underwent regular medical checkups in our hospital from March 2021 to March 2023 were studied,and the patients were divided into 2 groups of 60 patients each according to the random number table method.The study group was given Hesperidin capsules on the basis of lifestyle intervention(controlled diet and exercise)and the control group was given placebo(starch)capsules on the basis of lifestyle intervention.Fully automatic biochemical analyzer was used to determine the biochemical indexes of the patients,FibroScan was used to detect the patients'controlled attenuation parameters(CAP)and liver elastometry(LSM),and ELISA kit was used to determine the patients'ultrasensitive C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α)and nuclear factor-KB(NF-κB).Results:There was no significant difference between the baseline levels of the indicators in the two groups(P>0.05).Compared with baseline levels,patients in the study group had lower levels of CAP,alanine aminotransferase(ALT).gamma glutamatergic aminotranspeptidase(GGT),fasting glucose(FPG),fasting insulin(FIns),homeostasis model assessment method-insulin resistance index(HOMA-IR),cholesterol(CHOL)and levels of hs-CRP,TNF-α and NF-κB after 12 weeks(P<0.05).In contrast,compared with baseline levels,control patients had lower CAP,ALT,FIns and HOMA-IR levels and higher NF-κB levels after 12 weeks(P<0.05).In addition,CAP,GGT,triglyceride(TG)and CHOL levels and hs-CRP,TNF-α and NF-κB levels were reduced in patients in the study group after 12 weeks compared with the control group(P<0.05).Conclusion:Hesperidin supplementation reduced the degree of hepatic steatosis and decreased the levels of some liver enzymes,lipid distribution,and inflammation in NAFLD patients and may serve as a potential complementary therapeutic agent for NAFLD patients.